Edward Laane, MD, PhD1,2,3*, Purushothama Nanjappa2*, Subodh Kumar, PhD2,3*, Florence Magrangeas4*, Stephane Minvielle4*, Hele Everaus, MD, PhD5, Kenneth C Anderson, MD2, Herve Avet-Loiseau6,7*, Masood A Shammas, PhD2,3 and Nikhil C. Munshi, MD3,8
1North Estonia Medical Centre Foundation, Tallinn, Estonia
2The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
3VA Boston Healthcare System, West Roxbury, MA
4Centre de Recherche en Cancérologie Nantes-Angers UMR Inserm 892—CNRS 6299 and Institut de Recherche Thérapeutique de l’Université de Nantes (IRT-UN), Nantes, France
5Hematology-Oncology, Tartu University Hosptial, Tartu, Estonia
6IUCT-Oncopole, Toulouse, France
7Unité de Génomique du Myélome, CHU Rangueil, Toulouse, France
8Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA